Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

Canadian Cancer Trials Group IND.214 - A Phase I/II Study of MG1 MARABA/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients with Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours - was centrally activated October 31, 2014. We are anticipating first centre to be locally activated late next week and first patient on in November.